Publication details

Dapagliflozin a studie DECLARE – budoucnost léčby diabetes mellitus?

Title in English Dapagliflozin and the DECLARE study – the future of treating diabetes mellitus?
Authors

ŠPINAR Jindřich LÁBROVÁ Růžena

Year of publication 2016
Type Article in Periodical
Magazine / Source Kardiologická revue - Interní medicína
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords dapagliflozin; DECLARE; mortality
Description SGLT2 – gliflozins are a possible new treatment of diabetes mellitus type 2. The mechanism of action is excretion of glucose by the kidneys. The fi rst mortality clinical trial with SGLT2 empagliflozin was finished in 2015 and other studies are currently running. Dapaglifl ozin has a large clinical trial programme, and meta-analysis data from smaller studies have shown a decrease in cardiovascular endpoints. This eff ect is probably a result of several mechanisms: reduction in blood sugar; blood pressure lowering; reduction in weight; and a diuretic effect. DECLARE is an international clinical trial of dapagliflozin, which is also running in the Czech Republic; the suspected trial closure is in 2018-19. The dapagliflozin clinical trial programme does not only include diabetes mellitus type 2 patients, but also type 1, as well as pediatric patients.

You are running an old browser version. We recommend updating your browser to its latest version.

More info